Sugi Predict

Sugi Predict / Compounds / SCHEMBL629586

SCHEMBL629586

SCHEMBL629586

CC(C)(C)OC(=O)N1CC=CC1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.40
▸ PREP P48147 1/20 0.38
▸ CTSK P43235 1/20 0.37
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35
▸ USP2 O75604 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NR1H2 P55055 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL629585 1.00 ACE (0.47) ACEHSD17B10PREPCTSKCHRM2
SCHEMBL25175295 1.00 ACE (0.47) ACEHSD17B10PREPCTSKCHRM2
Diethylamine SCHEMBL28853511 0.90 ACE (0.43) ACEHSD17B10PREPCTSKSMN1; SMN2
SCHEMBL10137609 0.87 PREP (0.38) ACEHSD17B10PREPCTSKCHRM2
SCHEMBL31375026 0.87 PREP (0.38) ACEHSD17B10PREPCTSKCHRM2
SCHEMBL252768 0.87 HSD17B10 (0.54) HSD17B10SMN1; SMN2NPC1LMNANPSR1
SCHEMBL3915923 0.85 PREP (0.37) ACEHSD17B10PREPCTSKCHRM2
SCHEMBL1022805 0.85 PIN1 (0.42) ACEHSD17B10PREPCTSKCHRM2
SCHEMBL3546340 0.84 PTPN1 (0.39) ACEHSD17B10PREPCTSKCHRM2
SCHEMBL3546343 0.84 PTPN1 (0.39) ACEHSD17B10PREPCTSKCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504817-A Preparation and analysis method of 1-tert-butoxycarbonyl-2, 5-dihydro-1H-pyrrole-3-boric acid pinacol ester 新乡学院 2025-02-25 — — CN claimed
CN-115160205-B Method for preparing (S) -1- (tert-butoxycarbonyl) -2, 5-dihydro-1H-pyrrole-2-carboxylic acid and salt thereof 上海皓鸿生物医药科技有限公司 2024-06-07 — — CN claimed
CN-115160205-A Method for preparing (S) -1- (tert-butyloxycarbonyl) -2, 5-dihydro-1H-pyrrole-2-carboxylic acid and salt thereof 上海皓鸿生物医药科技有限公司 2022-10-11 — — CN claimed
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2026-01-27 — — US disclosed
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer ARTIOS PHARMA LIMITED (GB) 2025-07-15 — — US disclosed
CN-119504817-A Preparation and analysis method of 1-tert-butoxycarbonyl-2, 5-dihydro-1H-pyrrole-3-boric acid pinacol ester 新乡学院 2025-02-25 — — CN disclosed
CN-119504817-A Preparation and analysis method of 1-tert-butoxycarbonyl-2, 5-dihydro-1H-pyrrole-3-boric acid pinacol ester 新乡学院 2025-02-25 — — CN disclosed
WO-2025011610-A1 AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-01-16 — — WO disclosed
WO-2024188246-A9 NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海宇道生物技术有限公司 2024-12-05 — — WO disclosed
WO-2024188246-A1 NITROGEN-CONTAINING MACROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海宇道生物技术有限公司 2024-09-19 — — WO disclosed
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF HERCULES CAPITAL, INC., AS AGENT 2024-07-25 — — US disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 — — US disclosed
WO-2006017295-A2 TETRAPEPTIDE ANALOGS IDUN PHARMACEUTICALS, INC. (US) 2006-02-16 — — WO disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 — — EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 — — WO disclosed
US-6586405-B2 Therapy for blood disorders CORVAS INTERNATIONAL, INC. 2003-07-01 — — US disclosed
US-6479515-B1 FOR THE TREATMENT OF PAIN AND INFLAMMATION, AND ESPECIALLY IN THE TREATMENT OF ASTHMA, CEREBRAL TRAUMATIC SHOCK AND ALLERGIC RHINITIS FOURNIER INDUSTRIE ET SANTE (FR) 2002-11-12 — — US disclosed
US-20020037857-A1 Non-covalent inhibitors of urokinase and blood vessel formation CORVAS INTERNATIONAL, INC. 2002-03-28 — — US disclosed
EP-1182207-A2 Non-covalent inhibitors of urokinase and blood vessel formation CORVAS INTERNATIONAL, INC. (US) 2002-02-27 — — EP disclosed
WO-2002014349-A2 NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION CORVAS INTERNATIONAL, INC. (US) 2002-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020037857-A1 Non-covalent inhibitors of urokinase and blood vessel formation PLAU, PLAT, PLG ACE 302/4885HSD17B10 3242/4885PREP 193/4885
US-12534453-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS1, GYS2, GBA1 ACE 3734/4885HSD17B10 136/4885PREP 3122/4885
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS ACE 3804/4885HSD17B10 1043/4885PREP 1823/4885
US-20240246939-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF GYS2, GYS1, PYGL ACE 3305/4885HSD17B10 252/4885PREP 1535/4885
US-12358886-B2 Heterocyclic compounds for use in the treatment of cancer SDHA, DPYD, TP53 ACE 1298/4885HSD17B10 1094/4885PREP 1260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.